Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

GlobeNewswire 11 days ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

GlobeNewswire March 25, 2024

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

GlobeNewswire March 22, 2024

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601

GlobeNewswire January 22, 2024

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

GlobeNewswire January 8, 2024

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During "J.P. Morgan Week 2024"

GlobeNewswire December 21, 2023

Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

GlobeNewswire December 11, 2023

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire November 9, 2023

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

GlobeNewswire September 11, 2023

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 30, 2023

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Newsfile August 17, 2023

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

GlobeNewswire August 7, 2023

Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

GlobeNewswire July 26, 2023

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

GlobeNewswire July 10, 2023

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

GlobeNewswire June 26, 2023

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

GlobeNewswire June 12, 2023

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

GlobeNewswire May 31, 2023

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

GlobeNewswire May 8, 2023

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady(TM)

GlobeNewswire May 1, 2023